About this trial
The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subjects who have been diagnosed with connective tissue disease (CTD)-associated thrombocytopenia. And CTD includes primary Sjögren syndrome (according to the 2002 American College of Rheumatology (ACR)/ European League against Rheumatism (EULAR) classification criteria), systemic lupus erythematosus (SLE, according to the 1997 or the 2009 ACR classification criteria), and undifferentiated connective tissue disease (according to the 1999 international classification criteria)
50×10^9/L>PLT
anti-nuclear antibody (ANA) positive (≥1:80, any karyotype) detected in the laboratory of each research center
Standard therapy should be maintained stable for at least 14 days prior to the first dose of the experimental drug or placebo. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.)
Disqualifiers
Vital organ lethal bleeding (including but not limited to central nervous system bleeding, digestive tract bleeding) at screening, or intracranial bleeding 6 months prior to screening
Antiphospholipid syndrome, thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, or thrombocytopenia secondary to other causes (such as sepsis, Epstein-Barr virus infection, cytomegalovirus infection, Corona Virus Disease-19 (COVID-19) infection, drugs, etc.)
Hematopoietic system disorders, such as myelodysplastic syndrome, paroxysmal sleep hemoglobinuria, aplastic anemia, leukemia, lymphoma, myelofibrosis and so on
Severe cardiovascular system disease, including: unstable or uncontrollable disease or condition affecting the function of the heart (such as angina pectoris, congestive heart failure, uncontrolled hypertension or arrhythmia)
Trial design
Parallel
Treatments tested in this trial
Telitacicept
Biological/Vaccinesubcutaneous telitacicept 160 mg weekly for 24 weeks.
Placebo
Drugsubcutaneous placebo weekly for 24 weeks.
Treatment groups
Trial outcomes
Primary outcomes
Overall response (CR + PR) rate
Response is deemed as complete (CR) if the platelet (PLT) count is ≥ 100×10\^9/L, partial (PR) if the platelet count ranges from 50×10\^9/L to 100×10\^9/L and at least doubled from baseline. No active bleeding is allowed in participants classified as CR or PR.
Secondary outcomes
Overall response (CR + PR) rate
Response is deemed as complete (CR) if the platelet count is ≥ 100×10\^9/L, partial (PR) if the platelet count ranges from 50×10\^9/L to 100×10\^9/L and at least doubled from baseline. No active bleeding is allowed in participants classified as CR or PR.
Rescue treatment rate
Rescue treatment is initiated if the platelet count is \<10×10\^9/L, or the participant is with active bleeding, or based on the investigator's judgement when the platelet count ranges from 10×10\^9/L to 30×10\^9/L.
Time to rescue treatment
Time to rescue treatment refers to period duration from the initiation of Telitacicept or placebo (day 1) to rescue treatment.
Relapse rate
No response refers to the platelet count is \< 50×10\^9/L, or increases for less than 1-fold from baseline, or with active central nervous system or digestive tract bleeding, or rescue treatment is initiated. Relapse is defined as no response recurring after a complete or partial response lasting for at least 7 days with treatment.
Other outcomes
life quality 1
According to the ITP Patient Assessment Questionnaire™ (ITP-PAQ™) score. The ITP-PAQ™ is a disease-specific instrument that was designed to measure the Quality of Life (QoL) of adult patients with immune thrombocytopenia. The items employ a 4-week recall with responses recorded on 4-, 5- or 7-point Likert scales. All item scores are transformed to a 0 to 100 continuum where higher scores represent better QoL and are weighted equally to derive the scale scores.
life quality 2
According to the FACT-Th6 score. The Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th6) consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Items were reverse-scored as necessary such that higher scores represent higher Health-related quality of life (HRQoL). Total scores ranged from 0 to 24. Recall period is previous 7 days.
Absolute change rate from baseline in serum immunoglobulin G (IgG)
(serum IgG level at week 24-serum IgG level at baseline)/ serum IgG level at baseline
Absolute change rate from baseline in serum immunoglobulin M (IgM)
(serum IgM level at week 24-serum IgM level at baseline)/ serum IgM level at baseline
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Beijing Hospital
Lead sponsor
The First Affiliated Hospital of Anhui Medical University
Collaborator
The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Collaborator
Peking University People's Hospital
Collaborator
Peking University Third Hospital
Collaborator
First Affiliated Hospital, Sun Yat-Sen University
Collaborator
Guangdong Provincial People's Hospital
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
Second Xiangya Hospital of Central South University
Collaborator
Xiangya Hospital of Central South University
Collaborator
The Affiliated Hospital of Inner Mongolia Medical University
Collaborator
First Hospital of China Medical University
Collaborator
Shandong Provincial Hospital
Collaborator
Changhai Hospital
Collaborator
RenJi Hospital
Collaborator
Shanxi Bethune Hospital
Collaborator
West China Hospital
Collaborator
Institute of Hematology & Blood Diseases Hospital, China
Collaborator
Tianjin First Central Hospital
Collaborator
Tianjin Medical University General Hospital
Collaborator
People's Hospital of Xinjiang Uygur Autonomous Region
Collaborator
The First People's Hospital of Yunnan
Collaborator